Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

“With the approval of Journavx, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive ...

Journavx was evaluated in two random double ... "We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Kewalramani said.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine ... is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director ...

[Journavx] may help prevent the transition to chronic pain, reducing the need for long-term pain management strategies,” he said. Learn more about Journavx in the YouTube clip below.